MX371158B - Compuestos inhibidores de pde2. - Google Patents
Compuestos inhibidores de pde2.Info
- Publication number
- MX371158B MX371158B MX2017007380A MX2017007380A MX371158B MX 371158 B MX371158 B MX 371158B MX 2017007380 A MX2017007380 A MX 2017007380A MX 2017007380 A MX2017007380 A MX 2017007380A MX 371158 B MX371158 B MX 371158B
- Authority
- MX
- Mexico
- Prior art keywords
- organic compounds
- pharmaceuticals
- formula
- pharmaceutical compositions
- relates
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 abstract 1
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 abstract 1
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088541P | 2014-12-06 | 2014-12-06 | |
| PCT/US2015/064324 WO2016090380A1 (en) | 2014-12-06 | 2015-12-07 | Organic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017007380A MX2017007380A (es) | 2017-10-20 |
| MX371158B true MX371158B (es) | 2020-01-20 |
Family
ID=56092607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007380A MX371158B (es) | 2014-12-06 | 2015-12-07 | Compuestos inhibidores de pde2. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10300064B2 (enExample) |
| EP (1) | EP3226870B1 (enExample) |
| JP (1) | JP6608934B2 (enExample) |
| KR (1) | KR102557603B1 (enExample) |
| CN (1) | CN107205999B (enExample) |
| AU (1) | AU2015357496B2 (enExample) |
| BR (1) | BR112017012007B1 (enExample) |
| CA (1) | CA2969594A1 (enExample) |
| HK (1) | HK1243936A1 (enExample) |
| IL (1) | IL252579B (enExample) |
| MX (1) | MX371158B (enExample) |
| RU (1) | RU2709786C2 (enExample) |
| WO (1) | WO2016090380A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3970719A1 (en) | 2016-09-12 | 2022-03-23 | Intra-Cellular Therapies, Inc. | Pde1 inhibitor for use in a method of treatment or prophylaxis of inflammation and/or an inflammatory disease or disorder |
| SG11202010068VA (en) | 2018-04-25 | 2020-11-27 | Bayer Ag | Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides |
| WO2020086650A2 (en) * | 2018-10-23 | 2020-04-30 | Intra-Cellular Therapies, Inc. | Novel compounds |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603203A (en) | 1983-12-14 | 1986-07-29 | Takeda Chemical Industries, Ltd. | 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof |
| CA1251448A (en) | 1985-03-27 | 1989-03-21 | William J. Coates | Pyridazinone derivatives |
| US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
| DE59009485D1 (de) | 1989-01-26 | 1995-09-14 | Bayer Ag | Optisch aktive (Meth)Acrylsäure-Derivate, ihre Herstellung, ihre Polymerisation zu optisch aktiven Polymeren und deren Verwendung. |
| ZA914727B (en) | 1990-06-21 | 1992-03-25 | Schering Corp | Polycyclic guanine derivatives |
| US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| NZ262797A (en) | 1993-02-26 | 1997-08-22 | Schering Corp | Polycyclic guanine derivatives, purine and pyrimidine precursors; medicaments |
| DE19541264A1 (de) | 1995-11-06 | 1997-05-07 | Bayer Ag | Purin-6-on-derivate |
| US5824683A (en) | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
| DE19702785A1 (de) | 1997-01-27 | 1998-07-30 | Bayer Ag | Neue cyclische Harnstoffderivate |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| US6013621A (en) | 1997-10-17 | 2000-01-11 | The Rockfeller University | Method of treating psychosis and/or hyperactivity |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| DE19931206A1 (de) | 1999-07-07 | 2001-01-11 | Stief Christian | Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung |
| EP1222190A1 (en) | 1999-10-11 | 2002-07-17 | Pfizer Limited | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
| IL139073A0 (en) | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| CA2407031A1 (en) | 2000-04-19 | 2001-10-25 | Lilly Icos Llc | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease |
| WO2002009713A2 (de) | 2000-08-01 | 2002-02-07 | Bayer Aktiengesellschaft | Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung |
| DE10064105A1 (de) | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| MXPA04001891A (es) | 2001-08-28 | 2004-06-15 | Schering Corp | Inhibidores policiclicos de guanina fosfodiesterasa v. |
| WO2003020702A2 (en) | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| WO2003042216A1 (en) | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
| US20050153372A1 (en) | 2002-02-21 | 2005-07-14 | Paul Greengard | Compositions and method for regulation of calcium-dependent signaling in brain |
| WO2004041258A2 (fr) | 2002-10-30 | 2004-05-21 | Neuro3D | Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie |
| US7608716B2 (en) | 2002-11-06 | 2009-10-27 | Aska Pharmaceutical Co., Ltd. | Pyrazolonaphthyridine derivative |
| HRP20050848A2 (en) | 2003-03-04 | 2006-06-30 | Altana Pharma Ag | Purin-6-one-derivatives |
| WO2004087906A1 (en) | 2003-03-31 | 2004-10-14 | Pfizer Products Inc. | Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
| EA200501548A1 (ru) | 2003-04-01 | 2006-02-24 | Апплайд Резеч Системз Арс Холдинг Н.В. | Ингибиторы фосфодиэстераз при бесплодии |
| US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| GEP20094720B (en) | 2003-12-16 | 2009-06-25 | Pfizer Prod Inc | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| WO2005083069A1 (en) * | 2004-01-30 | 2005-09-09 | Pfizer Products Inc. | Pde2 crystal structures for structure based drug design |
| BRPI0514586A (pt) | 2004-09-02 | 2008-06-17 | Altana Pharma Ag | triazolftalazinas |
| MX2007008137A (es) | 2005-01-05 | 2007-07-19 | Altana Pharma Ag | Triazoloftalazinas como inhibidores de pde2. |
| CA2591991C (en) | 2005-01-05 | 2013-11-19 | Altana Pharma Ag | Triazolophthalazines |
| DOP2006000009A (es) * | 2005-01-13 | 2006-08-15 | Arena Pharm Inc | Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina |
| WO2006133261A2 (en) | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP1749824A1 (en) | 2005-08-03 | 2007-02-07 | Neuro3D | Benzodiazepine derivatives, their preparation and the therapeutic use thereof |
| US20080194592A1 (en) | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
| CN101268073B (zh) | 2005-09-15 | 2011-10-19 | Aska制药株式会社 | 杂环化合物、制备方法及其用途 |
| US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
| JP5453086B2 (ja) | 2006-06-06 | 2014-03-26 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| US9198924B2 (en) | 2006-11-13 | 2015-12-01 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2089034A4 (en) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | NEW USES |
| MX2009011830A (es) | 2007-05-11 | 2009-11-13 | Pfizer | Compuestos amino-heterociclicos. |
| US7807629B1 (en) | 2007-06-05 | 2010-10-05 | Alcon Research, Ltd. | Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma |
| WO2009073210A1 (en) | 2007-12-06 | 2009-06-11 | Intra-Cellular Therapies, Inc | Organic compounds |
| CN104370920A (zh) | 2007-12-06 | 2015-02-25 | 武田药品工业株式会社 | 有机化合物 |
| WO2010062366A1 (en) | 2008-10-31 | 2010-06-03 | Arginetix, Inc. | Compositions and methods of treating endothelial disorders |
| WO2010054253A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
| WO2010054260A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| EA201170772A1 (ru) | 2008-12-06 | 2012-03-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| WO2010065148A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX2011005935A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| BRPI0922700A2 (pt) | 2008-12-06 | 2015-08-11 | Intracellular Therapies Inc | Compostos orgânicos |
| EA201170771A1 (ru) | 2008-12-06 | 2012-01-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| JP5778582B2 (ja) | 2008-12-06 | 2015-09-16 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| EP2400970A4 (en) | 2009-02-25 | 2012-07-18 | Intra Cellular Therapies Inc | PDE-1-HEMMER FOR EYE DRESSING |
| US9468637B2 (en) | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2011011312A1 (en) | 2009-07-22 | 2011-01-27 | Merck Sharp & Dohme Corp. | Quinolinone pde2 inhibitors |
| JP2013507360A (ja) | 2009-10-08 | 2013-03-04 | イントラ−セルラー・セラピーズ・インコーポレイテッド | ホスホジエステラーゼ１−標的トレーサーおよび方法 |
| WO2011049722A1 (en) | 2009-10-19 | 2011-04-28 | Merck Sharp & Dohme Corp. | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
| US9371327B2 (en) | 2010-05-31 | 2016-06-21 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| AP2013007070A0 (en) * | 2011-02-23 | 2013-08-31 | Pfizer | Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders |
| EP2718295A1 (en) * | 2011-06-07 | 2014-04-16 | Pfizer Inc | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
| JP2014526453A (ja) | 2011-09-09 | 2014-10-06 | ハー・ルンドベック・アクチエゼルスカベット | ピリジン化合物およびそれらの使用 |
| WO2013034755A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders |
| WO2013034758A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Substituted triazolopyrazines and uses thereof |
| AR091507A1 (es) | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| US9598426B2 (en) | 2013-03-15 | 2017-03-21 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2016515541A (ja) | 2013-03-25 | 2016-05-30 | サノフイ | Ｍｅｔａｐ２阻害剤（２型メチオニンアミノペプチターゼ）としてのピラゾロナフチリジノン誘導体 |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
-
2015
- 2015-12-07 US US15/533,527 patent/US10300064B2/en active Active
- 2015-12-07 EP EP15865341.0A patent/EP3226870B1/en active Active
- 2015-12-07 KR KR1020177018721A patent/KR102557603B1/ko active Active
- 2015-12-07 HK HK18103471.2A patent/HK1243936A1/zh unknown
- 2015-12-07 CA CA2969594A patent/CA2969594A1/en active Pending
- 2015-12-07 RU RU2017123686A patent/RU2709786C2/ru active
- 2015-12-07 AU AU2015357496A patent/AU2015357496B2/en not_active Ceased
- 2015-12-07 WO PCT/US2015/064324 patent/WO2016090380A1/en not_active Ceased
- 2015-12-07 JP JP2017530036A patent/JP6608934B2/ja not_active Expired - Fee Related
- 2015-12-07 MX MX2017007380A patent/MX371158B/es active IP Right Grant
- 2015-12-07 BR BR112017012007-0A patent/BR112017012007B1/pt not_active IP Right Cessation
- 2015-12-07 CN CN201580073695.9A patent/CN107205999B/zh not_active Expired - Fee Related
-
2017
- 2017-05-29 IL IL252579A patent/IL252579B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017536410A (ja) | 2017-12-07 |
| RU2017123686A (ru) | 2019-01-09 |
| CA2969594A1 (en) | 2016-06-09 |
| EP3226870B1 (en) | 2019-09-25 |
| US10300064B2 (en) | 2019-05-28 |
| MX2017007380A (es) | 2017-10-20 |
| RU2709786C2 (ru) | 2019-12-20 |
| BR112017012007A2 (pt) | 2017-12-26 |
| EP3226870A1 (en) | 2017-10-11 |
| JP6608934B2 (ja) | 2019-11-20 |
| IL252579A0 (en) | 2017-07-31 |
| BR112017012007B1 (pt) | 2022-11-01 |
| US20170360792A1 (en) | 2017-12-21 |
| AU2015357496B2 (en) | 2019-09-19 |
| KR102557603B1 (ko) | 2023-07-19 |
| CN107205999B (zh) | 2021-08-03 |
| KR20170089000A (ko) | 2017-08-02 |
| WO2016090380A1 (en) | 2016-06-09 |
| HK1243933A1 (zh) | 2018-07-27 |
| HK1243936A1 (zh) | 2018-07-27 |
| AU2015357496A1 (en) | 2017-07-27 |
| EP3226870A4 (en) | 2018-05-30 |
| RU2017123686A3 (enExample) | 2019-07-17 |
| CN107205999A (zh) | 2017-09-26 |
| IL252579B (en) | 2021-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
| MX373320B (es) | Compuestos inhibidores de pde2. | |
| NZ739676A (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
| PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| MX378194B (es) | Compuestos organicos. | |
| PH12016501192B1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| TW201613911A (en) | Heterocyclic compounds and uses thereof | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| PH12017502255B1 (en) | Nrf2 regulators | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| AU2015207757A8 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
| TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
| MX2017008444A (es) | Picolinamidas como fungicidas. | |
| MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
| EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
| MX2017014035A (es) | Formas solidas novedosas. | |
| MX2018015125A (es) | Nuevos compuestos antibacterianos. | |
| HK1245257A1 (zh) | 具有广谱活性的抗菌化合物 | |
| TW201613934A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| EA033460B1 (ru) | Замещенные [1,2,4]триазольные соединения в качестве фунгицидов | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| PH12016501613B1 (en) | Pyrazines modulators of gpr6 | |
| MX2017007380A (es) | Compuestos organicos. | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |